23
May
2025
23
May
2025
Dry eye sufferers know the frustration of discomfort, irritation, and ongoing treatment routines. A new clinical study offers hope: a thermomechanical action (TMA) device known as Tixel C may be just as effective—and potentially more convenient—than traditional thermal pulsation methods. This blog explores the key findings of a recent multicentre, randomised study comparing Tixel to the established LipiFlow system, shedding light on what this could mean for Meibomian Gland Dysfunction (MGD) treatment.
Effectiveness_and_safety_of_a_thermomechanical.-Novoxel.pdf
To view the PDF please click here.
1. Tear Break-Up Time (TBUT)
- Both devices showed significant improvement at 4 and 12 weeks.
- Tixel was non-inferior to LipiFlow, meeting the primary study endpoint.
2. Symptom Relief (OSDI Scores)
- OSDI scores improved in both groups, with slightly greater gains in the Tixel group at 12 weeks.
3. Gland Function (MGS Scores)
- Both groups experienced notable improvements in meibomian gland function.
4. Drop Usage and Pain Scores
- Participants used fewer lubricant drops post-treatment, with mild discomfort reported in both groups.
- Pain scores were slightly higher for Tixel but remained low overall.
- Radiation-Free: Tixel uses brief thermal pulses with no radiation or gel required.
- No Eye Contact: The device doesn’t touch the ocular surface, enhancing comfort.
- Portable and Efficient: Each session takes just 2 minutes per eye.
- FDA Cleared: Tixel is now cleared for evaporative dry eye treatment in the US.
This clinical trial shows that Tixel is a safe and effective alternative to LipiFlow for treating MGD-related dry eye. With its non-contact design and efficient treatment time, it offers eye care professionals a compelling new tool for managing a widespread and often debilitating condition.
Arrange an in-clinic demonstration to explore how Tixel® can support your clinical outcomes
Read it? Loved it? Want to share it?
